FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023442722> ?p ?o ?g. }

• W2023442722 endingPage "19773" @default.
• W2023442722 startingPage "19773" @default.
• W2023442722 abstract "Purpose Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being used in clinical practice in Spain and Portugal. Our aim was to present the clinical experience with this regimen in a cohort of adult HIV-infected antiretroviral (ARV)-naïve patients. Methods Retrospective, multicentre, cohort study. Consecutive adult HIV-infected ARV-naïve HLA-B*5701-negative patients, who started ABC/3TC/NVP between 2005-2013, with at least one follow-up visit, were included. Demographic, clinical and laboratory variables were assessed at baseline, month 1, and every three–four months thereafter. The primary end point was HIV-1 viral load (VL)<40 c/mL at 48 weeks. Data were analyzed by intent-to-treat (ITT) (switch=failure, and missing=failure) and on treatment (OT) analyses. Results 78 patients were included. Median follow up was 26 (0.1-84) months. 86% were male, median age 41 (23-69) years, 9% had AIDS, 8% were HCV+, baseline CD4 was 275 (10-724) cells/µL and median VL 4.58 (3.02-6.92) log. After 48 weeks, VL was<40 c/mL in 89.8% (OT), 79.7% (M=F) and 65.4% (S=F) and at 96 weeks in 88.5%, 78.9% and 61.6%, respectively. CD4 increased +246 (p<0.001) and +292 (p<0.001) cells/uL after 48 and 96 weeks, respectively. One or more drugs of the regimen were discontinued in 33 (42.3%) patients. In 15 (19.2%) patients (13 NVP, 2 ABC/3TC) therapy was stopped due to toxicity after a median of one month (in only two cases after six months of follow up): 80% of them had rash/liver toxicity. Six (7.7%) patients discontinued ART due to virologic failure, five (6.4%) because of other reasons and seven (9%) were lost to follow-up. ALT but not AST significantly increased (+0.07 ukat/L at 96 weeks, p=0.033). A significant increase of 25%, 26% and 42% in total cholesterol, LDLc and HDLc, respectively, and a significant decrease in TC/HDL ratio (6%, p=0.008) was observed after 96 weeks. Conclusions Despite a considerable proportion of patients had to stop therapy due to toxicity (most associated with NVP), those initially tolerating this regimen presented a high virologic and immunologic response after 96 weeks, as well as a favourable lipid profile. ABC/3TC/NVP may be a suitable alternative first regimen, mainly in countries with economic constraints." @default.
• W2023442722 created "2016-06-24" @default.
• W2023442722 creator A5001557481 @default.
• W2023442722 creator A5012384912 @default.
• W2023442722 creator A5019558090 @default.
• W2023442722 creator A5024385877 @default.
• W2023442722 creator A5029931096 @default.
• W2023442722 creator A5029992759 @default.
• W2023442722 creator A5036522089 @default.
• W2023442722 creator A5045428298 @default.
• W2023442722 creator A5048798397 @default.
• W2023442722 creator A5053140952 @default.
• W2023442722 creator A5053844368 @default.
• W2023442722 creator A5069673103 @default.
• W2023442722 creator A5072944678 @default.
• W2023442722 creator A5075908129 @default.
• W2023442722 date "2014-11-01" @default.
• W2023442722 modified "2023-10-17" @default.
• W2023442722 title "Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients" @default.
• W2023442722 doi "https://doi.org/10.7448/ias.17.4.19773" @default.
• W2023442722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4225404" @default.
• W2023442722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25397517" @default.
• W2023442722 hasPublicationYear "2014" @default.
• W2023442722 type Work @default.
• W2023442722 sameAs 2023442722 @default.
• W2023442722 citedByCount "2" @default.
• W2023442722 countsByYear W20234427222015 @default.
• W2023442722 countsByYear W20234427222016 @default.
• W2023442722 crossrefType "journal-article" @default.
• W2023442722 hasAuthorship W2023442722A5001557481 @default.
• W2023442722 hasAuthorship W2023442722A5012384912 @default.
• W2023442722 hasAuthorship W2023442722A5019558090 @default.
• W2023442722 hasAuthorship W2023442722A5024385877 @default.
• W2023442722 hasAuthorship W2023442722A5029931096 @default.
• W2023442722 hasAuthorship W2023442722A5029992759 @default.
• W2023442722 hasAuthorship W2023442722A5036522089 @default.
• W2023442722 hasAuthorship W2023442722A5045428298 @default.
• W2023442722 hasAuthorship W2023442722A5048798397 @default.
• W2023442722 hasAuthorship W2023442722A5053140952 @default.
• W2023442722 hasAuthorship W2023442722A5053844368 @default.
• W2023442722 hasAuthorship W2023442722A5069673103 @default.
• W2023442722 hasAuthorship W2023442722A5072944678 @default.
• W2023442722 hasAuthorship W2023442722A5075908129 @default.
• W2023442722 hasBestOaLocation W20234427221 @default.
• W2023442722 hasConcept C126322002 @default.
• W2023442722 hasConcept C142462285 @default.
• W2023442722 hasConcept C197934379 @default.
• W2023442722 hasConcept C203014093 @default.
• W2023442722 hasConcept C2522874641 @default.
• W2023442722 hasConcept C2777869810 @default.
• W2023442722 hasConcept C2778375690 @default.
• W2023442722 hasConcept C2779130552 @default.
• W2023442722 hasConcept C2779465607 @default.
• W2023442722 hasConcept C2780593183 @default.
• W2023442722 hasConcept C2781413609 @default.
• W2023442722 hasConcept C2993143319 @default.
• W2023442722 hasConcept C3013748606 @default.
• W2023442722 hasConcept C71924100 @default.
• W2023442722 hasConcept C72563966 @default.
• W2023442722 hasConcept C90924648 @default.
• W2023442722 hasConceptScore W2023442722C126322002 @default.
• W2023442722 hasConceptScore W2023442722C142462285 @default.
• W2023442722 hasConceptScore W2023442722C197934379 @default.
• W2023442722 hasConceptScore W2023442722C203014093 @default.
• W2023442722 hasConceptScore W2023442722C2522874641 @default.
• W2023442722 hasConceptScore W2023442722C2777869810 @default.
• W2023442722 hasConceptScore W2023442722C2778375690 @default.
• W2023442722 hasConceptScore W2023442722C2779130552 @default.
• W2023442722 hasConceptScore W2023442722C2779465607 @default.
• W2023442722 hasConceptScore W2023442722C2780593183 @default.
• W2023442722 hasConceptScore W2023442722C2781413609 @default.
• W2023442722 hasConceptScore W2023442722C2993143319 @default.
• W2023442722 hasConceptScore W2023442722C3013748606 @default.
• W2023442722 hasConceptScore W2023442722C71924100 @default.
• W2023442722 hasConceptScore W2023442722C72563966 @default.
• W2023442722 hasConceptScore W2023442722C90924648 @default.
• W2023442722 hasLocation W20234427221 @default.
• W2023442722 hasLocation W20234427222 @default.
• W2023442722 hasLocation W20234427223 @default.
• W2023442722 hasLocation W20234427224 @default.
• W2023442722 hasLocation W20234427225 @default.
• W2023442722 hasOpenAccess W2023442722 @default.
• W2023442722 hasPrimaryLocation W20234427221 @default.
• W2023442722 hasRelatedWork W1991708878 @default.
• W2023442722 hasRelatedWork W2022055721 @default.
• W2023442722 hasRelatedWork W2023442722 @default.
• W2023442722 hasRelatedWork W2052534463 @default.
• W2023442722 hasRelatedWork W2061249771 @default.
• W2023442722 hasRelatedWork W2119628015 @default.
• W2023442722 hasRelatedWork W2164864370 @default.
• W2023442722 hasRelatedWork W2322202895 @default.
• W2023442722 hasRelatedWork W2732854388 @default.
• W2023442722 hasRelatedWork W2953641579 @default.
• W2023442722 hasVolume "17" @default.
• W2023442722 isParatext "false" @default.
• W2023442722 isRetracted "false" @default.
• W2023442722 magId "2023442722" @default.
• W2023442722 workType "article" @default.